Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Role of SGLT2 Inhibitors in Type 2 Diabetes With Chronic Kidney Disease
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: July 12, 2022 Expiration: July 11, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Bayer HealthCare Pharmaceuticals Inc.
Jennifer B. Green, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate current and emerging clinical data on the use of SGLT2 inhibitors in the management of CKD

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Jennifer B. Green, MD: consultant/advisor/speaker: Bayer.

Staff

Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP, has no relevant financial relationships to disclose.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant financial relationships to disclose.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD has no relevant financial relationships to disclose.
Julie Skowronski, FNP-BC
Julie Skowronski, NP has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for nephrologists, endocrinologists, primary care physicians, and specialty and primary care advanced practice providers.

Goal

The goal of this activity is to improve healthcare professionals’ competence in the management of T2D-associated CKD, including the clinical evidence, place in therapy, and optimization of medication regimens for patients with CKD receiving an SGLT2 inhibitor and/or finerenone.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 12, 2022, through July 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Role of SGLT2 Inhibitors in Type 2 Diabetes With Chronic Kidney Disease
  • CME
  • CE

Loading...
In this microlearning module, an expert faculty provides an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes.
Jennifer B. Green, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: July 12, 2022 Expiration: July 11, 2023

Related Content

Concise microlearning module featuring expert insight on the cardiorenal benefits of finerenone in T2D and CKD from Clinical Care Options (CCO)

Vivian A. Fonseca, MD, FRCP
Program Director
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: August 4, 2022 Expired: August 3, 2023

Commentary on clinical use of SGLT2 inhibitors in diabetic kidney disease, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 21, 2022

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 12, 2022

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of finerenone in patients with type 2 diabetes, from Clinical Care Options (CCO)

Released: July 7, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings